Abstract
Recent studies have illustrated the important role of alloantibodies in mediating renal allograft rejection. Compared to T-cell mediated-rejection, antibody-mediated rejection is usually more refractory to conventional anti-rejection treatment and more likely to contribute to allograft failure. Antibody-mediated rejection can occur in three principal forms: hyperacute, acute, and chronic active. This brief review aims to characterize the main pathological features attributed to antibody-mediated rejection including light microscopy manifestations, ultrastructural alterations, and immunopathologic markers.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
